+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type, Product, Test, Application - Global Forecast 2025-2030- Product Image
Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type, Product, Test, Application - Global Forecast 2025-2030- Product Image
Sale

Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type, Product, Test, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010865
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Obstructive Pulmonary Disease Treatment Market grew from USD 77.50 billion in 2023 to USD 83.39 billion in 2024. It is expected to continue growing at a CAGR of 7.69%, reaching USD 130.24 billion by 2030.

The Chronic Obstructive Pulmonary Disease (COPD) treatment market encompasses pharmaceuticals, medical devices, and lifestyle management practices aimed at alleviating symptoms and slowing disease progression. COPD, a common respiratory condition often caused by smoking and environmental pollutants, requires diverse treatment options. The market is driven by an aging global population, increasing prevalence of smoking, and heightened awareness of respiratory diseases. Applications of COPD treatments include reducing airflow limitation, managing acute exacerbations, and improving patients' quality of life. End-users primarily encompass hospitals, clinics, and homecare settings, requiring comprehensive treatment plans. Key factors influencing market growth include advancements in inhaler technologies, personalized medicine, and an increase in collaborations for drug development. Opportunities lie in emerging markets with rising healthcare expenditures and advancements in telehealth for remote patient monitoring. The ongoing integration of artificial intelligence in diagnostic tools also offers potential for enhanced disease management and personalized treatment plans. However, limitations such as high treatment costs, stringent regulatory frameworks, and side effects of medications pose significant challenges. Moreover, the competitive landscape, dominated by well-established pharmaceutical giants, may hinder market entry for smaller players. Innovative areas for growth include research on novel drug delivery systems, development of biologics, and exploration of non-pharmacological interventions like pulmonary rehabilitation. Success in this market necessitates a robust understanding of regional healthcare policies and patient needs, combined with strategic partnerships for R&D. To navigate challenges and leverage opportunities, businesses should focus on cost-effective solutions and evidence-based healthcare interventions. Overall, the COPD treatment market is poised for growth with continuous innovation being crucial to fulfilling unmet medical needs and addressing the dynamic nature of healthcare demands.

Understanding Market Dynamics in the Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increase in geriatric population and rise in unhealthy lifestyle
    • Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
    • Increasing consumer awareness toward digital asthma care devices
  • Market Restraints
    • Stringent regulations for inhaler approvals by the government
  • Market Opportunities
    • Rapid technological advancements and new product launches in the asthma devices
    • High demand for home care therapeutic devices
  • Market Challenges
    • Increased pricing pressures and patent expiries on inhalers

Exploring Porter’s Five Forces for the Chronic Obstructive Pulmonary Disease Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Chronic Obstructive Pulmonary Disease Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Chronic Obstructive Pulmonary Disease Treatment Market

External macro-environmental factors deeply influence the performance of the Chronic Obstructive Pulmonary Disease Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Chronic Obstructive Pulmonary Disease Treatment Market

The Chronic Obstructive Pulmonary Disease Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Obstructive Pulmonary Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, S.A., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Orion Oyj, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chronic Obstructive Pulmonary Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Antibiotic
    • Anticholinergic
    • Beta2-agonists
    • Methylxanthines
    • Oral Corticosteroid
    • Phosphodiesterase-4 Inhibitors
  • Product
    • Inhalers
    • Nebulizers
  • Test
    • Arterial Blood Gas Test
    • Chest X-ray Test
    • CT scan
    • Genetic Test
    • Lung Functional Test
  • Application
    • Chronic Bronchitis
    • Emphysema
    • Refractory Asthma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in geriatric population and rise in unhealthy lifestyle
5.1.1.2. Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
5.1.1.3. Increasing consumer awareness toward digital asthma care devices
5.1.2. Restraints
5.1.2.1. Stringent regulations for inhaler approvals by the government
5.1.3. Opportunities
5.1.3.1. Rapid technological advancements and new product launches in the asthma devices
5.1.3.2. High demand for home care therapeutic devices
5.1.4. Challenges
5.1.4.1. Increased pricing pressures and patent expiries on inhalers
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Type
6.1. Introduction
6.2. Antibiotic
6.3. Anticholinergic
6.4. Beta2-agonists
6.5. Methylxanthines
6.6. Oral Corticosteroid
6.7. Phosphodiesterase-4 Inhibitors
7. Chronic Obstructive Pulmonary Disease Treatment Market, by Product
7.1. Introduction
7.2. Inhalers
7.3. Nebulizers
8. Chronic Obstructive Pulmonary Disease Treatment Market, by Test
8.1. Introduction
8.2. Arterial Blood Gas Test
8.3. Chest X-ray Test
8.4. CT scan
8.5. Genetic Test
8.6. Lung Functional Test
9. Chronic Obstructive Pulmonary Disease Treatment Market, by Application
9.1. Introduction
9.2. Chronic Bronchitis
9.3. Emphysema
9.4. Refractory Asthma
10. Americas Chronic Obstructive Pulmonary Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA2-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ARTERIAL BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHEST X-RAY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LUNG FUNCTIONAL TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REFRACTORY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 43. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 47. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 65. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 69. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 77. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 101. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 114. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 118. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 122. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 126. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 138. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 150. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 153. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 154. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 156. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 158. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 174. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 186. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 196. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Chronic Obstructive Pulmonary Disease Treatment market, which are profiled in this report, include:
  • Abbott Laboratories
  • Adamis Pharmaceuticals Corporation
  • Almirall, S.A.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Chiesi Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Oyj
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 83.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 130.24 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class, Distribution Channel - Global Forecast 2025-2030 - Product Image

Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 343 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.